This page contains brief information about melphalan hydrochloride and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Melphalan hydrochloride is approved to treat:
- Multiple myeloma.
- It is used for palliative treatment in patients who cannot take melphalan by mouth. This use is approved for the Alkeran and Evomela brands.
- It is used as a conditioning treatment to prepare patients for a stem cell transplant. This use is approved for the Evomela brand.
Melphalan hydrochloride is also being studied in the treatment of other types of cancer.
Melphalan is also available in a tablet form. For more information, see the Drug Information Summary for Melphalan.
More About Melphalan Hydrochloride
MedlinePlus Information on Melphalan Hydrochloride – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Clinical Trials Accepting Patients
Find Clinical Trials for Melphalan Hydrochloride – Check for trials from TCH’s list of cancer clinical trials now accepting patients.